Saturday, June 25, 2022

Athira Pharma Inc. [ATHA] stock for 104,880 USD was acquired by Romano Kelly A

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Athira Pharma Inc. shares valued at $104,880 were purchased by Romano Kelly A on Mar 31. At $13.11 per share, Romano Kelly A acquired 8,000 shares. The insider’s holdings grew to 8,315 shares worth approximately $23697.75 following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


As published in their initiating research note from BTIG Research on May 10, 2022, Athira Pharma Inc. [ATHA] has been a Buy and the price target has been revised to $33. This represents a 91.36% premium over Wednesday’s closing price. Analysts at Berenberg started covering the stock with ‘”a Buy”‘ outlook in a report released in late April. As of December 15, 2021, Goldman has initiated its “Neutral” rating for ATHA. Earlier on October 13, 2020, Stifel initiated its rating. Their recommendation was “a Buy” for ATHA stock.

Analyzing ATHA’s Price Performance

On Wednesday, Athira Pharma Inc. [NASDAQ: ATHA] plunged -66.27% to $2.85. The stock’s lowest price that day was $2.53, but it reached a high of $3.10 in the same session. During the last five days, there has been a drop of approximately -64.51%. Over the course of the year, Athira Pharma Inc. shares have dropped approximately -78.13%. Shares of the company reached a 52-week high of $14.22 on 04/04/22 and a 52-week low of $2.53 on 06/22/22. A 50-day SMA is recorded $9.45, while a 200-day SMA reached $10.98. Nevertheless, trading volume fell to 21.84 million shares from 0.35 million shares the previous day.

Support And Resistance Levels for Athira Pharma Inc. (ATHA)

According to the 24-hour chart, there is a support level at 2.55, which, if violated, would cause prices to drop to 2.26. In the upper region, resistance lies at 3.12. The next price resistance is at 3.40. RSI (Relative Strength Index) is 16.01 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.55, which suggests the price will decrease in the coming days. Percent R is at 95.67%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Athira Pharma Inc. subject to short interest?

Stocks of Athira Pharma Inc. saw a sharp rise in short interest on Apr 28, 2022 jumping by 0.42 million shares to 2.7 million. Data from Yahoo Finance shows that the short interest on Mar 30, 2022 was 2.28 million shares. A jump of 15.56% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.93 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.93.

Which companies own the most shares of Athira Pharma Inc. (ATHA)?

According to Perceptive Advisors LLC filings, the company currently owns 3,425,916 shares, which is about 9.10% of the total ATHA shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 3425916.0 shares. With the completion of the sale, BlackRock Fund Advisors’s stake is now worth $20,067,263. Franklin Advisers, Inc. reduced a -5.43% interest valued at $17.86 million while RTW Investments LP sold a 0 stake. A total of 187,293 shares of Athira Pharma Inc. were sold by Pathstone Family Office LLC during the quarter, and -18,458 were sold by The Vanguard Group, Inc. In its current portfolio, Wasatch Advisors, Inc. holds 1,274,791 shares valued at $11.58 million.

In terms of Athira Pharma Inc. share price expectations, FactSet research, analysts set an average price target of $26.50 in the next 12 months, up nearly 290.53% from the previous closing price of $8.45. Analysts anticipate Athira Pharma Inc. stock to reach $51.00 by 2022, with the lowest price target being $3.00. In spite of this, 6 analysts ranked Athira Pharma Inc. stock as an Overweight at the end of 2022. On October 13, 2020, JMP Securities assigned a price target of “a Mkt outperform” to the stock and initiated coverage with a $51.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam